How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

TT

NASDAQ:TTNP
Get a brief AI stock analysisSaves ~ 15 minutes of your time

TT

Titan Pharmaceuticals IncNASDAQ TTNP Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is TTNP undervalued compared to its fair value?

The fair value of TTNP stock is hidden USD. Relative to the market price of 5.778 USD Titan Pharmaceuticals Inc is hidden.

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in San Franc...[More about valuation]

Titan Pharmaceuticals Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.005 $B

Price:

5.778 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.45

FINANCIALS

Titan Pharmaceuticals financial for reporting period

Income Statement

0 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0003 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0 B 100%
-0.0021 B -51525%
-0.0003 B -8450%

Balance Sheet

0.01 B
0.0081 B

0.0005 B

Financial Position Analysis

Assets

0.01 B
Current Assets
0.0099 B
Total non-current assets
0.0001 B

Total current liabilities
0.0019 B
Total non-current liabilities

Cash Flow Statement

-0.0013 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0018 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Titan Pharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-300 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-145 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Titan Rating

Is TTNP attractive for investment based on fundamental analysis?

TTNP stock rating is hidden. Titan Pharmaceuticals is a hidden by Eyestock methodology.

Get TTNP Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-2 032

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

1.823

Debt / Equity ratio:

0.061

ROE:

-300

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

TTNP analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for TTNP to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Titan Pharmaceuticals Inc dividends

TTNP dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About TTNP stock

About the company Titan Pharmaceuticals Inc

Market cap $B

0.005

Dividend yield

Shares outstanding

14.6292 B

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.

TTNP profile

  • Ticker

    TTNP

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    18 January 1996

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    11

  • City

    San Francisco

  • Address

    Suite 505, 400 Oyster Point Blvd

  • Cusip

    888314606

Frequently Asked Questions

What sector does Titan operate in?

Titan operates in Healthсare sector

What is market cap of Titan?

Market cap of Titan is 0.005 USD as of 24 Jul 2024

What is market price of one TTNP stock?

Market price of one TTNP stock is 5.7781 USD as of 24 Jul 2024

What is Titan revenue?

According to the recent report Titan revenue is 0.004

What is Titan net income?

According to the recent report Titan net icnome is -0.338

What is Titan net income growh rate?

Net income growth rate of Titan is -149